Despite of the expanding oncology pipeline, cancer vaccines contribute only to a minor share of total oncology-attributed revenues owing to the limited number of approved products. Although, the FDA approved a personalized vaccine Sipuleucel-T (Provenge) for men with metastatic prostate cancer in 2010. Cancer vaccine development is well known for its high development costs and risks, low historical rates of investment return, high probability of failures arising in ventures, partnerships and alliances. The cost of reimbursement for novel oncology therapies is not universally acceptable to payers limiting the potential for a global expansion, market access and reducing probability of commercial success.
However, a positive light can be thrown on the upcoming cancer therapeutic vaccines, which boosts the immune system's ability to recognize and destroy antigens. The current research and development is focussed more on developing personalized vaccines. These types of vaccines are produced from the person's tumor sample. Other cancer vaccines target specific cancer antigens and are given to people whose tumors have those antigens on the surface of the tumor cells. The major vaccine types in development are peptide vaccines, dendritic cell vaccines, mRNA and DNA based vaccines and neo-antigen vaccines through novel technology platforms.
The upcoming market of cancer vaccines is blooming with promising therapeutic vaccine. In terms of the cancer indications, the most benefitted one's with respect to a good number of upcoming vaccines by major key players are prostate cancer (Advantagene), NSCLC (OSE immunotherapuetics), pancreatic cancer (Nantkwest), melanoma, followed by DLBCL, Breast cancer and colorectal cancers. Other cancers such as Bladder cancer, Glioblastoma's, Microsatellite Instability-High Cancers, Anal and Rectal cancers are also under the light of development with equally potential therapeutic vaccines.
Highlighting the major key players' along with their potential developments in trial, such as Advantagene's Prostatak and OSE immunotherapeutics' Tedopi will be the first to market position due to their early launches in the United States, EU5 Countries followed by Japan. While other potential players are Moderna and Neon Therapeutics.
Out of the 20+ promising therapeutic cancer vaccines ((there are 100+ in total), including 14+ indications in high stages of development most of them are targeting recurrent and advanced stages of cancer, except the one being developed for first line treatment of patients with Glioblastoma Multiforme.
Another major key players are Nantkwest and Immunovaccine technologies, in terms of targeting the maximum number of cancer indications. Nantkwest's hank vaccine is being evaluated in combination with avelumab for Triple Negative Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma and Pancreatic Cancer along with few other indications in early stages of testing. While Immunovaccine technologies's DPX-Survivac (Survivin) is being developed in combination with Keytruda for Ovarian cancer, DLBCL, NSCLC, bladder, HCC, melanoma along with few other cancers.
These budding vaccines are majorly tested in combination with radiation therapy, chemotherapy, adjuvants with either their respective standard of care (SOC) therapies or I-O therapies involving PD-1/PD-L1 such as pemrolizumab, nivolumab etc. It's mesmerizing that not just the upcoming vaccine market is expected to boom in the coming years, but along it will also strengthen the already existing market of blockbuster PD-1/PD-L1 inhibitors, fulfilling the best choice for adjuvants.
In conclusion, therapeutic cancer vaccines have the potential to address several unmet needs that persist in cancer treatment paradigm currently. It's likely that they will prove their value as high efficacy, promising and low-toxicity treatment options for early-stage disease and by enhancing the efficacy of existing regimens in late-stage disease.
In this report we have captured the commercial potential of all potential cancer treatment vaccine targeting multiple indications in next 10-15 years.
TABLE OF CONTENTS
1. KEY INSIGHTS
2. CANCER VACCINES MARKET OVERVIEW AT A GLANCE
- 2.1. MARKET SHARE (%) DISTRIBUTION OF CANCER VACCINES IN 2017
- 2.2. MARKET SHARE (%) DISTRIBUTION OF CANCER VACCINES IN 2030
3. DISEASE BACKGROUND AND OVERVIEW: CANCER VACCINES
- 3.1. INTRODUCTION
- 3.2. STRATEGIES FOR CANCER VACCINE IMMUNOTHERAPY
- 3.3. TYPES OF TUMOR VACCINES
- 3.3.1. Whole-cell vaccines
- 3.3.2. Antigen Based Vaccines
- 3.3.3. Antigen Presenting Cell Vaccines
- 3.3.4. Nonspecific and Cytokine Strategies
- 3.4. CANCER VACCINE ANTIGENS
- 3.4.1. Tumor-associated antigens
- 3.4.2. Oncogenic viral antigens
- 3.4.3. Neoantigens
- 3.5. VACCINE VECTORS
- 3.5.1. Cellular vaccines
- 3.5.2. Peptide vaccines
- 3.5.3. Viral vector vaccines
- 3.5.4. DNA and RNA vaccines
- 3.6. COMBINATIONS WITH OTHER THERAPIES
- 3.7. MARKETED CANCER VACCINES
- 3.8. RESEARCH
- 3.9. SIDE EFFECTS OF CANCER VACCINES
4. MARKETED DRUGS
- 4.1. MARKETED DRUGS KEY-CROSS COMPETITION
- 4.2. PROVENGE (SIPULEUCEL-T): DENDREON CORPORATION/SANPOWER GROUP
- 4.2.1. Drug Description
- 4.2.1. Regulatory Milestones
- 4.2.2. Other Development Activities
- 4.2.3. Safety and Efficacy
- 4.2.4. Product Profile
5. EMERGING DRUGS
- 5.1. KEY CROSS COMPETITION
- 5.2. KEY CROSS COMPETITION OF PHASE I VACCINES
- 5.3. PROSTATAK: ADVANTAGENE
- 5.3.1. Product Description
- 5.3.2. Other Developmental Activities
- 5.3.3. Clinical Development
- 5.3.4. Product Profile
- 5.4. TEDOPI (OSE2101): OSE IMMUNOTHERAPEUTICS
- 5.4.1. Product Description
- 5.4.2. Other Developmental Activities
- 5.4.3. Clinical Development
- 5.4.4. Product Profile
- 5.5. DCVAC/OVCA: SOTIO
- 5.5.1. Product Description
- 5.5.2. Other Developmental Activities
- 5.5.3. Clinical Development
- 5.5.4. Product Profile
- 5.6. DCVAC/PCA: SOTIO
- 5.6.1. Product Description
- 5.6.2. Other Developmental Activities
- 5.6.3. Clinical Development
- 5.6.4. Product Profile
- 5.7. AXALIMOGENE FILOLISBAC (ADXS11-001; ADXS-HPV): ADVAXIS
- 5.7.1. Product Description
- 5.7.2. Other Developmental Activities
- 5.7.3. Clinical Development
- 5.7.4. Product Profile
- 5.8. HEPCORTESPENLISIMUT-L (HEPKO-V5; V5): IMMUNITOR
- 5.8.1. Product Description
- 5.8.2. Other Developmental Activities
- 5.8.3. Clinical Development
- 5.8.4. Product Profile
- 5.9. DCVAC/LUCA: SOTIO
- 5.9.1. Product Description
- 5.9.2. Other Developmental Activities
- 5.9.3. Clinical Development
- 5.9.4. Product Profile
- 5.10. VX-001: VAXON BIOTECH
- 5.10.1. Product Description
- 5.10.2. Other Developmental Activities
- 5.10.3. Clinical Development
- 5.10.4. Product Profile
- 5.11. TLPLDC VACCINE: ELIOS THERAPEUTICS
- 5.11.1. Product Description
- 5.11.2. Other Developmental Activities
- 5.11.3. Clinical Development
- 5.11.4. Product Profile
- 5.12. MRNA-4157 + PEMBROLIZUMAB: MODERNATX
- 5.12.1. Product Description
- 5.12.2. Other Developmental Activities
- 5.12.3. Clinical Development
- 5.12.4. Product Profile
- 5.13. GRANITE (GRT-C901) + SLATE (GRT-R902): GRITSTONE ONCOLOGY
- 5.13.1. Product Description
- 5.13.2. Other Developmental Activities
- 5.13.3. Clinical Development
- 5.13.4. Product Profile
- 5.14. HANK VACCINE: NANTKWEST
- 5.14.1. Product Description
- 5.14.2. Other Developmental Activities
- 5.14.3. Clinical Development
- 5.14.4. Product Profile
- 5.15. GVAX VACCINE : ADURO BIOTECH
- 5.15.1. Product Description
- 5.15.2. Other Developmental Activities
- 5.15.3. Clinical Development
- 5.15.4. Product Profile
- 5.16. DC VACCINE: AIM IMMUNOTECH
- 5.16.1. Product Description
- 5.16.2. Other Developmental Activities
- 5.16.3. Clinical Development
- 5.16.4. Product Profile
- 5.17. POLYPEPI1018 VACCINE: TREOS BIO
- 5.17.1. Product Description
- 5.17.2. Other Developmental Activities
- 5.17.3. Clinical Development
- 5.17.4. Product Profile
- 5.18. RV001V: RHOVAC
- 5.18.1. Product Description
- 5.18.2. Other Developmental Activities
- 5.18.3. Clinical Development
- 5.18.4. Product Profile
- 5.19. SURVIVIN (DPX-SURVIVAC VACCINE): IMMUNOVACCINE TECHNOLOGIES
- 5.19.1. Product Description
- 5.19.2. Other Developmental Activities
- 5.19.3. Clinical Development
- 5.19.4. Product Profile
- 5.20. AD-MAGEA3 AND MG1-MAGEA3: TURNSTONE BIOLOGICS
- 5.20.1. Product Description
- 5.20.2. Other Developmental Activities
- 5.20.3. Clinical Development
- 5.20.4. Product Profile
- 5.21. DENDRITIC CELL-BASED P53 VACCINE + NIVOLUMAB + IPILIMUMAB: MULTIVIR
- 5.21.1. Product Description
- 5.21.2. Other Developmental Activities
- 5.21.3. Clinical Development
- 5.21.4. Product Profile
- 5.22. ISA101/ISA101B: ISA PHARMACEUTICALS
- 5.22.1. Product Description
- 5.22.2. Other Developmental Activities
- 5.22.3. Clinical Development
- 5.22.4. Product Profile
- 5.23. GEN-009 ADJUVANTED VACCINE: GENOCEA BIOSCIENCES
- 5.23.1. Product Description
- 5.23.2. Other Developmental Activities
- 5.23.3. Clinical Development
- 5.23.4. Product Profile
- 5.24. IMU-131 (HER-VAXX): IMUGENE
- 5.24.1. Product Description
- 5.24.2. Other Developmental Activities
- 5.24.3. Clinical Development
- 5.24.4. Product Profile
- 5.25. TG01 VACCINE: TARGOVAX
- 5.25.1. Product Description
- 5.25.2. Other Developmental Activities
- 5.25.3. Clinical Development
- 5.25.4. Product Profile
- 5.26. ITI-1000 (PP65 DC VACCINE): IMMUNOMIC THERAPEUTICS
- 5.26.1. Product Description
- 5.26.2. Other Developmental Activities
- 5.26.3. Clinical Development
- 5.26.4. Product Profile
6. THERAPEUTIC ASSESSMENT
- 6.1. MAJOR KEY PLAYERS - BASED ON NUMBER OF INDICATIONS
- 6.2. BY PHASES
- 6.3. BY VACCINE TYPES
- 6.4. BY ROUTE OF ADMINISTRATION
- 6.5. BY TARGET INDICATION OF KEY PLAYERS
7. COMPARISON OF CANCER VACCINES BY TECHNOLOGY
8. ATTRIBUTE ANALYSIS OF CANCER VACCINES
9. CANCER VACCINES: 7 MAJOR MARKET ANALYSIS
- 9.1. KEY FINDINGS
- 9.2. MARKET SIZE OF CANCER VACCINES IN THE 7MM
- 9.3. UNITED STATES MARKET SIZE
- 9.3.1. Total Market size of Cancer Vaccines
- 9.3.2. Market Size by Therapies
- 9.4. GERMANY MARKET SIZE
- 9.4.1. Total Market size of Cancer Vaccines in Germany
- 9.4.2. Market Size by Therapies
- 9.5. FRANCE MARKET SIZE
- 9.5.1. Total Market Size of Cancer Vaccines
- 9.5.2. Market Size by Therapies
- 9.6. ITALY MARKET SIZE
- 9.6.1. Total Market Size of Cancer Vaccines
- 9.6.2. Market Size by Therapies
- 9.7. SPAIN MARKET SIZE
- 9.7.1. Total Market Size of Cancer Vaccines
- 9.7.2. Market Size by Therapies
- 9.8. UNITED KINGDOM MARKET SIZE
- 9.8.1. Total Market Size of Cancer Vaccines
- 9.8.2. Market Size by Therapies
- 9.9. JAPAN MARKET SIZE
- 9.9.1. Total Market Size of Cancer Vaccines
- 9.9.2. Market Size by Therapies
10. CASE REPORTS
- 10.1. DENDREON CORPORATION FILES FOR BANKRUPTCY AS PROVENGE FAILS TO MAKE PROFITS
11. SWOT ANALYSIS FOR CANCER VACCINES
12. LIMITATIONS OF CANCER TREATMENT VACCINES
13. APPENDIX
- 13.1. BIBLIOGRAPHY
- REPORT METHODOLOGY
14. DELVEINSIGHT CAPABILITIES
15. DISCLAIMER
16. ABOUT DELVEINSIGHT
比較リスト
